These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 16884869)
21. Segmented polyurethane intravaginal rings for the sustained combined delivery of antiretroviral agents dapivirine and tenofovir. Johnson TJ; Gupta KM; Fabian J; Albright TH; Kiser PF Eur J Pharm Sci; 2010 Feb; 39(4):203-12. PubMed ID: 19958831 [TBL] [Abstract][Full Text] [Related]
22. Proxyphylline release kinetics from symmetrical three-layer silicone rubber matrices: effect of different excipients in the outer rate-controlling layers. Soulas DN; Sanopoulou M; Papadokostaki KG Int J Pharm; 2012 May; 427(2):192-200. PubMed ID: 22330934 [TBL] [Abstract][Full Text] [Related]
23. The use of supersaturation for the vaginal application of microbicides: a case study with dapivirine. Grammen C; Plum J; Van Den Brande J; Darville N; Augustyns K; Augustijns P; Brouwers J J Pharm Sci; 2014 Nov; 103(11):3696-3703. PubMed ID: 25231545 [TBL] [Abstract][Full Text] [Related]
24. A novel intravaginal ring to prevent HIV-1, HSV-2, HPV, and unintended pregnancy. Ugaonkar SR; Wesenberg A; Wilk J; Seidor S; Mizenina O; Kizima L; Rodriguez A; Zhang S; Levendosky K; Kenney J; Aravantinou M; Derby N; Grasperge B; Gettie A; Blanchard J; Kumar N; Roberts K; Robbiani M; Fernández-Romero JA; Zydowsky TM J Control Release; 2015 Sep; 213():57-68. PubMed ID: 26091920 [TBL] [Abstract][Full Text] [Related]
25. Sustained release of proteins from a modified vaginal ring device. Morrow RJ; Woolfson AD; Donnelly L; Curran R; Andrews G; Katinger D; Malcolm RK Eur J Pharm Biopharm; 2011 Jan; 77(1):3-10. PubMed ID: 21055465 [TBL] [Abstract][Full Text] [Related]
26. Combination Pod-Intravaginal Ring Delivers Antiretroviral Agents for HIV Prophylaxis: Pharmacokinetic Evaluation in an Ovine Model. Moss JA; Butkyavichene I; Churchman SA; Gunawardana M; Fanter R; Miller CS; Yang F; Easley JT; Marzinke MA; Hendrix CW; Smith TJ; Baum MM Antimicrob Agents Chemother; 2016 Jun; 60(6):3759-66. PubMed ID: 27067321 [TBL] [Abstract][Full Text] [Related]
27. Development and evaluation of accelerated drug release testing methods for a matrix-type intravaginal ring. Externbrink A; Eggenreich K; Eder S; Mohr S; Nickisch K; Klein S Eur J Pharm Biopharm; 2017 Jan; 110():1-12. PubMed ID: 27793758 [TBL] [Abstract][Full Text] [Related]
28. Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring. Externbrink A; Clark MR; Friend DR; Klein S Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):966-73. PubMed ID: 23791685 [TBL] [Abstract][Full Text] [Related]
29. Compartmental transport model of microbicide delivery by an intravaginal ring. Geonnotti AR; Katz DF J Pharm Sci; 2010 Aug; 99(8):3514-21. PubMed ID: 20222027 [TBL] [Abstract][Full Text] [Related]
30. Safety and availability of dapivirine (TMC120) delivered from an intravaginal ring. Romano J; Variano B; Coplan P; Van Roey J; Douville K; Rosenberg Z; Temmerman M; Verstraelen H; Van Bortel L; Weyers S; Mitchnick M AIDS Res Hum Retroviruses; 2009 May; 25(5):483-8. PubMed ID: 19388819 [TBL] [Abstract][Full Text] [Related]
31. Regulation of proxyphylline's release from silicone rubber matrices by the use of osmotically active excipients and a multi-layer system. Soulas DN; Papadokostaki KG Int J Pharm; 2011 Apr; 408(1-2):120-9. PubMed ID: 21335074 [TBL] [Abstract][Full Text] [Related]
32. Preparation and evaluation of bromocryptine mesylate-polydimethylsiloxane matrices. Acartürk F; Altuğ N Pharmazie; 2000 Sep; 55(9):668-71. PubMed ID: 11031770 [TBL] [Abstract][Full Text] [Related]
33. [Preparation and release mechanism of gestodene reservoir-type intravaginal rings]. Li CX; Wang YK; Ning MY Yao Xue Xue Bao; 2014 Mar; 49(3):399-405. PubMed ID: 24961114 [TBL] [Abstract][Full Text] [Related]
34. Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. Clark JT; Johnson TJ; Clark MR; Nebeker JS; Fabian J; Tuitupou AL; Ponnapalli S; Smith EM; Friend DR; Kiser PF J Control Release; 2012 Oct; 163(2):240-8. PubMed ID: 22981701 [TBL] [Abstract][Full Text] [Related]
36. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]
37. An intravaginal ring for the sustained delivery of antibodies. Gunawardana M; Baum MM; Smith TJ; Moss JA J Pharm Sci; 2014 Nov; 103(11):3611-3620. PubMed ID: 25231193 [TBL] [Abstract][Full Text] [Related]
38. An Intravaginal Ring for the Simultaneous Delivery of an HIV-1 Maturation Inhibitor and Reverse-Transcriptase Inhibitor for Prophylaxis of HIV Transmission. Ugaonkar SR; Clark JT; English LB; Johnson TJ; Buckheit KW; Bahde RJ; Appella DH; Buckheit RW; Kiser PF J Pharm Sci; 2015 Oct; 104(10):3426-39. PubMed ID: 26149293 [TBL] [Abstract][Full Text] [Related]
39. Development of dapivirine vaginal ring for HIV prevention. Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702 [TBL] [Abstract][Full Text] [Related]
40. Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimisation by an artificial neural network. Woolfson AD; Umrethia ML; Kett VL; Malcolm RK Int J Pharm; 2010 Mar; 388(1-2):136-43. PubMed ID: 20045043 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]